Clinical Significance of Circulating Immune Complexes Detection in Chronic Glomerulonephritis

Gluckman, Jean-Claude; Jacob, Noam; Beaufils, H; Baumelou, A; Salah, Hisham; German, A; Legrain, M

doi:10.1159/000181435

Cited by 17 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immune complex measurement in SLE by other assays have had variable results. Concordance of disease activity and IC levels has been reported for the Clq deviation test (13) and the polyclonal latex agglutination inhibition test (14), while the lymphocyte rosette inhibition assay correlated poorly with activity (15). The Raji cell assay and the monoclonal rheumatoid factor assay (16) showed concordance with nonrenal disease but not with renal disease.…”

Section: Discussionmentioning

confidence: 91%

The C1q binding assay in systemic lupus erythematosus

Inman

Fong

Pussell

et al. 1980

Arthritis & Rheumatism

View full text Add to dashboard Cite

To investigate the relationship of Clq binding assay (ClqBA) to disease activity in systemic lupus erythematosus (SLE), a retrospective study was carried out on 232 ClqBA performed in 33 patients with SLE.When initial values only were assessed (33 tests in 33 patients), there was no relationship between positive and negative ClqBA and abnormal renal function (P = 0.482, Fisher exact test). Of 87 tests performed during active renal disease, 34 (39%) were positive; of 48 tests during active non-renal disease, 25 (52%) were positive; of 83 tests when the disease was inactive, 45 (54%) were positive; and of 14 tests during episodes of infection, 10 (71%) were positive. Corresponding means for the ClqBA were as follows: renal 65.66, non-renal78.02, inactive 56.04, infection 135.79 (no significant diarerences by Student's f-test). There was no significant relationship with the ClqBA when comparing active disease (renal and non-renal) with inactive disease ($ Yates = 1.875, P = 0.171). When renal function abnormalities were analyzed separately, the ClqBA values were inde-

show abstract

Section: Discussionmentioning

confidence: 91%

The C1q binding assay in systemic lupus erythematosus

Inman

Fong

Pussell

et al. 1980

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…Circulating immune complexes have been detected with varying success in the sera of glomerulonephritic patients [10,13,31,42], In IgA nephropathy patients the results have usually been negative [6]. This may reflect the inability of most methods to detect IgA complexes.…”

Section: Discussionmentioning

confidence: 99%

Circulating Immune Complexes, the Concentration of Serum IgA and the Distribution of HLA Antigens in IgA Nephropathy

Mustonen¹,

Pasternack²,

Helin³

et al. 1981

Nephron

View full text Add to dashboard Cite

A series of 40 IgA nephropathy patients is presented. IgA nephropathy was the most common (24%) type of glomerulonephritis in our renal biopsy material. Circulating immune complexes were measured by five methods that gave a positive result in 9–69% of the patients. The platelet aggregation test with heated serum (PAT2) was by far the most commonly positive. The serum concentrations of IgA were measured by two methods, radial immunodiffusion and laser nephelometry. Both tests gave similar results. 58% of the patients had elevated serum IgA. There was no statistically significant association between HLA antigens and IgA nephropathy as compared with the control material.

show abstract

“…Serum complement levels, such as C3 and C4, are typically normal, and in some IgAN patients, even elevated [ 64 ], as are complement components C1q and C2-C9 [ 64 , 65 , 66 , 67 , 68 ]. Nonetheless, the utility of complement proteins in the circulation as prognostic biomarkers in IgAN is still under investigation [ 52 , 61 ].…”

Section: Complement System Inhibitorsmentioning

confidence: 99%

An Update on the Current State of Management and Clinical Trials for IgA Nephropathy

Cheung

Rajasekaran

Barratt

et al. 2021

JCM

View full text Add to dashboard Cite

IgA nephropathy remains the most common primary glomerular disease worldwide. It affects children and adults of all ages, and is a leading cause of end-stage kidney disease, making it a considerable public health issue in many countries. Despite being initially described over 50 years ago, there are still no disease specific treatments, with current management for most patients being focused on lifestyle measures and renin-angiotensin-aldosterone system blockade. However, significant advances in the understanding of its pathogenesis have been made particularly over the past decade, leading to great interest in developing new therapeutic strategies, and a significant rise in the number of interventional clinical trials being performed. In this review, we will summarise the current state of management of IgAN, and then describe major areas of interest where new therapies are at their most advanced stages of development, that include the gut mucosal immune system, B cell signalling, the complement system and non-immune modulators. Finally, we describe clinical trials that are taking place in each area and explore future directions for translational research.

show abstract

Clinical Significance of Circulating Immune Complexes Detection in Chronic Glomerulonephritis

Cited by 17 publications

References 7 publications

The C1q binding assay in systemic lupus erythematosus

The C1q binding assay in systemic lupus erythematosus

Circulating Immune Complexes, the Concentration of Serum IgA and the Distribution of HLA Antigens in IgA Nephropathy

An Update on the Current State of Management and Clinical Trials for IgA Nephropathy

Contact Info

Product

Resources

About